Serum Markers - Mesothelioma

Soluble Mesothelin-Related Peptide Level Elevation in Mesothelioma Serum and Pleural Effusions
Harvey I. Pass, MD, Anil Wali, PhD, Naimei Tang, PhD, Alla Ivanova, PhD, Sergey Ivanov, PhD, Michael Harbut, MD, Michele Carbone, MD, PhD, and Jeffrey Allard, PhD Department of Cardiothoracic Surgery, Division of Thoracic Surgery, New York University School of Medicine, New York, New York; Karmanos Cancer Institute, Detroit, Michigan; Cancer Research Center of Hawaii, Honolulu, Hawaii; and Fujirebio Diagnostics Inc, Malvern, Pennsylvania.

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelin.
Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, Yokoyama A, Hamada H, Fujii Y, Yamaguchi K, Hirashima T, Matsui K, Tachibana I, Nakamura Y, Kawase I, Naka T. Department of Respiratory Medicine, Allergy, and Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan; Laboratory for Immune Signal, National Institute of Biomedical Innovation, 7-6-8 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan.

[New diagnostic markers for malignant pleural mesothelioma]
Grigoriu BD, Grégoire M, Chahine B, Scherpereel A. Inserm U774, Institut Pasteur, Lille, France.

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Department of Cardiothoracic Surgery, Division of Thoracic Surgery, New York University School of Medicine, New York, New York 10016, USA. harvey.pass@med.nyu.edu

Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma.
Weber DG, Taeger D, Pesch B, Kraus T, Brüning T, Johnen G. BG Institute for Occupational Medicine (BGFA), Ruhr University of Bochum, Bochum, Germany.

Non-invasive diagnosis of pleural malignancies: the role of tumour markers.
van den Heuvel MM, Korse CM, Bonfrer JM, Baas P. Department of Thoracic Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Assessment of tumor response in malignant pleural mesothelioma.
Ceresoli GL, Chiti A, Zucali PA, Cappuzzo F, De Vincenzo F, Cavina R, Rodari M, Poretti D, Lutman FR, Santoro A. Department of Medical Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy. giovanni_luca.ceresoli@humanitas.it

Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW. National Research Centre for Asbestos Related Diseases, 4th Floor, G Block, Sir Charles Gairdner Hospital, Verdun St, Nedlands, WA 6009, Australia. creaneyj@cyllene.uwa.edu.au

Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P. Institut National de la Sante et de la Recherche Medicale (INSERM) U774, Institut Pasteur de Lille, Lille, France.

Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma.
Frey AB, Wali A, Pass H, Lonardo F. Department of Pathology, Harper University Hospital, and Karmanos Cancer Institute, 3990 John R. Street, Detroit, MI 48201, USA.

Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results.
Di Serio F, Fontana A, Loizzi M, Capotorto G, Maggiolini P, Mera E, Bisceglia L, Molinini R. Department of Clinical Pathology I, University Hospital of Bari, Bari, Italy. diseriofrancesca@tiscali.it

MESOMARK: a potential test for malignant pleural mesothelioma.
Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I, Hellstrom KE, Miller MC, Verch T, Allard WJ, Pass HI, Sardesai NY. Research and Development Division, Fujirebio Diagnostics, Inc., Malvern, PA 19355, USA.

Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P. INSERM Unit 774, Institut Pasteur de Lille, 59037 Lille Cedex, France. a-scherpereel@chru-lille.fr

A Binding Domain on Mesothelin for CA125/MUC16.
Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, Ho M. Laboratory of Molecular Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892.

Kinetics of Soluble Mesothelin in Patients with Malignant Pleural Mesothelioma During Treatment.
Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A. INSERM Unit 774, Institut Pasteur de Lille, Rue du pr. calmette, Lille, 59000, France; Department of Pulmonary Diseases, University of Medicine and Pharmacy, Iasi, Romania.


 


Believe in a Cure!

Contact us here for immediate expert help and a free copy of the book "100 Questions & Answers About Mesothelioma."

(877) END-MESO
(877) 363-6376